title: [Expression and prognostic significance of TOSO in CD19+ B cells from Chinese CLL patients].
abstract: OBJECTIVE
  To investigate the expression and its prognostic significance of TOSO in CD19(+) B cells from Chinese chronic lymphocytic leukemia (CLL) patients.
  
  
  METHODS
  The expression of TOSO was detected by absolute quantitative reverse transcription-polymerase chain reaction (RT-PCR) in a cohort of 85 untreated CLL patients from March 2006 to September 2010. Their status of immunoglobulin heavy chain variable (IGVH) somatic mutation, ZAP70 and CD38 were analyzed.
  
  
  RESULTS
  The expression of TOSO was significantly elevated in CLL patients versus the healthy population (8.30 ± 2.99 vs 6.63 ± 1.22, P = 0.036) and other B cell lymphoproliferative diseases (8.30 ± 2.99 vs 7.12 ± 1.13, P = 0.023). The expression of TOSO was elevated in the IGVH non-mutated group versus the mutated group (9.87 ± 1.08 vs 7.61 ± 3.03, P = 0.000). The expression of TOSO was significantly elevated in Binet stage C patients versus in Binet stage B and Binet stage A patients (9.91 ± 3.03 vs 8.73 ± 1.86 vs 7.27 ± 2.83, P = 0.000). The expression of TOSO rose to (9.37 ± 2.12) in the chemotherapy group. And it was significantly higher than that in the observation group (7.19 ± 3.23, P = 0.001). At the cut-off point of 55 years old, the younger patients had a higher expression of TOSO than the elders (9.10 ± 2.06 vs 7.95 ± 3.22, P = 0.049). The expression of TOSO in ZAP70 and CD38-positive groups had no difference with those in the negative groups.
  
  
  CONCLUSIONS
  The over-expressed TOSO in CLL cells is associated with a progressive disease. It may be an important prognostic factor for CLL.
authors.affiliation: State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Yu
authors.forename: Ke-shu
authors.initials: KS
authors.lastname: Zhou
authors.forename: Zeng-jun
authors.initials: ZJ
authors.lastname: Li
authors.forename: Shu-hua
authors.initials: SH
authors.lastname: Yi
authors.forename: Mu
authors.initials: M
authors.lastname: Hao
authors.forename: Chang-hong
authors.initials: CH
authors.lastname: Li
authors.forename: Jun-yuan
authors.initials: JY
authors.lastname: Qi
authors.forename: Lu-gui
authors.initials: LG
authors.lastname: Qiu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018941:Antigens, CD19 / Q000276:immunology; D051017:Apoptosis Regulatory Proteins / Q000235:genetics*; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics* / Q000276:immunology / Q000378:metabolism*; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis
chemical_list: D018941:Antigens, CD19; D051017:Apoptosis Regulatory Proteins; C112037:FCMR protein, human; D008565:Membrane Proteins